DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
IMC-1C11 is an investigational drug.
There have been 78 clinical trials for IMC-1C11. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2015.
The most common disease conditions in clinical trials are Carcinoma, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Eli Lilly and Company, National Cancer Institute (NCI), and ImClone LLC.
There are fourteen US patents protecting this investigational drug and one hundred and twenty international patents.
Recent Clinical Trials for IMC-1C11
|Crystalloid Fluid Choice and Neurological Outcome in Patients After Subarachnoid Haemorrhage||University Hospital Inselspital, Berne||N/A|
|Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab||Immunocore Ltd||Phase 1/Phase 2|
|Olaparib and Ceralasertib in Treating Patients With IDH Mutant Cholangiocarcinoma or Solid Tumors||National Cancer Institute (NCI)||Phase 2|
Top disease conditions for IMC-1C11
Top clinical trial sponsors for IMC-1C11
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|IMC-1C11||Start Trial||Method and compositions for treating cancerous tumors||Start Trial|
|IMC-1C11||Start Trial||Quinolines derivatives as novel anticancer agents||GENOSCIENCE PHARMA (Marseilles, FR)||Start Trial|
|IMC-1C11||Start Trial||Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy||THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (Philadelphia, PA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|